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Summary
Carbon monoxide can be formed when volatile anaesthetic agents such as desflurane and
sevoflurane are used with anaesthetic breathing systems containing carbon dioxide absorbents. This
review describes the possible chemical processes involved and summarises the experimental and
clinical evidence for the generation of carbon monoxide. We emphasise the different conditions
that were used in the experimental work, and explain some of the features of the clinical reports.
Finally, we provide guidelines for the prevention and detection of this complication.
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It has long been known that inhalation anaesthetic agents
are broken down and that carbon monoxide (CO) can be
formed by that breakdown in the presence of carbon
dioxide (CO2) absorbents. Initial anecdotal reports sug-
gested that soda lime and Baralyme* absorbent (Table 1)
could produce CO from inhaled anaesthetics. The first
cases involved enflurane [1] and isoflurane [2]. Thirty-one
cases of intra-operative CO poisoning were described,
with some CO concentrations exceeding 1000 parts per
million and carboxyhaemoglobin (COHb) concentrations
reaching 30% or more. With desflurane, COHb concen-
trations of 32% were reported [3, 4]. In vitro experiments
showed that with dried absorbents, CO production was
in the following order: desflurane > enflurane > isoflu-
rane and was trivial with halothane and sevoflurane [5].
Degradation appears to be inversely related to the water
content of the absorbent and occurs more with Baralyme
than with soda lime. It was shown in vitro that the
rehydration of desiccated Baralyme prevents CO forma-
tion from desflurane [6]. A difluoromethoxy group is a
structural requirement for halo ether degradation to CO
[7]. The typical case of CO poisoning is the first patient
on a Monday morning (Monday morning disease), when
after the weekend an anaesthetic machine is used through
which high gas flows had been maintained, resulting in
drying of the absorbent.
CO production
Early studies found that sevoflurane was less stable than
might be desired and that it breaks down at a rate
determined by temperature: 13% over 1 h at 40 C and
56% at 60 C [8]. Baralyme produced a four-fold greater
degradation of sevoflurane than did soda lime
(0.66 ml.min)1 vapour vs. 0.17 ml.min)1), inducing a
slight delay at the start of anaesthesia [9]. Degradation to
compound A was inhibited by chilling the soda lime
canister to 26 C [10]. Baralyme dehydration increased
and soda lime dehydration decreased the concentration of
compound A in an in vitro model [11]. Until 2000 it was
thought that the breakdown of sevoflurane was more or
less associated with the production of compound A and
that among the inhalation anaesthetics, CO production
was mainly associated with desflurane. Indeed, in pigs
anaesthetised with desflurane, high COHb concentrations
were found when the CO2 absorbent was partially dried
[12]. With dehydrated Baralyme, peak CO concentra-
tions of 37 000 ± 3500 parts per million and COHb
concentrations of > 80% were found. It came as a surprise
when Holak et al. reported that, with sevoflurane in*Baralyme was withdrawn from the market in August 2004.
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specific experimental circumstances in vitro, the genera-
tion of 11 000 parts per million CO occurred, followed
by an explosion and fire when the canister temperature
exceeded 200 C [13]. It is therefore of interest to review
all the known in vitro and in vivo assessments concerning
the production of CO, particularly with sevoflurane, and
to describe the scarce clinical data on this problem.
Laboratory studies with small amounts of soda lime
and strict temperature control
In an early effort to analyse the production of CO, barrels
of simple 30-ml syringes were used with the open ends
sealed with rubber corks, pierced with a needle through
which gases were passed [5]. Dried and partially dried
(1.4–9.7% water) absorbents (soda lime and Baralyme)
were examined. Desflurane, enflurane and isoflurane
were analysed at 25–45 C, and halothane and sevo-
flurane at 45–60 C. The magnitude of CO production
was in the order: desflurane ‡ enflurane > isoflurane ‡
halothane ¼ sevoflurane. Completely dry soda lime pro-
duced more CO than partially dry soda lime. Baralyme
produced more CO than soda lime. An increased,
controlled absorbent temperature increased CO produc-
tion. At 60 C the peak CO concentrations were only
79 parts per million with 3.6% sevoflurane (Table 2). In
another study, sealed 20.7-ml vials were used which
contained desiccated absorbent and a filter paper onto
which anaesthetics were injected for volatilisation [7].
CO formation from desflurane, enflurane and isoflurane
was greater with Baralyme (containing 4.6% potassium
hydroxide) than with soda lime (containing only 2.5%
potassium hydroxide), probably through greater base-
catalysed difluoromethoxy proton removal with potas-
sium than sodium hydroxide (Fig. 1). Sevoflurane and
halothane formed only negligible amounts of CO. These
two laboratory studies with only small amounts of
absorbents did not indicate any real problem from CO
production with sevoflurane.
In vitro studies using clinical absorber systems
In more clinically relevant studies, larger amounts of CO2
absorbents were studied in standard canisters with no
control of absorbent temperature. Halothane, enflurane
and isoflurane were assessed in a Dra¨ger ISO system filled
with completely dried CO2 absorbent [14]. Peak CO of
3500 parts per million was recorded with enflurane and
isoflurane. Although maximal CO concentrations of only
450 parts per million were found with halothane, the
temperature increased to 50 C and more. Interestingly,
it took about 75 min to attain a measurable halothane
concentration. These findings suggest that halothane is
absorbed in dried soda lime, with an exothermic chemical
reaction between the absorbent and the anaesthetic. In an
almost identical study, desflurane, enflurane, isoflurane
and sevoflurane were passed through completely dried
Dra¨gersorb 800 soda lime for 2–3 days [15]. In contrast to
the hydrated CO2 absorbent, with the dried absorbent a
temperature increase was found with all the anaesthetics
and was more pronounced with sevoflurane (120–
130 C) than with the other anaesthetics (desflurane
56–58 C). Water condensation at the inspiratory valve
was also noticed with sevoflurane and later also in the
Table 1 Brand and composition of CO2
absorbents mentioned in this review.
Brand Company
NaOH
(%)
KOH
(%)
Ca(OH)2
(%)
CaCl2
(%)
Ba(OH)2
(%)
Baralyme Chemetron, St. Louis, MO – 5.3 74 – 11
Soda lime Several 2–4 1–3 94 – –
Dra¨gersorb 800 Dra¨ger, Lu¨beck, Germany 2 3 79 – –
Dra¨gerSorb Free Dra¨ger, Lu¨beck, Germany 3–5 – 74–82 3–5 –
Sofnolime Molecular product, Thaxed, UK 3 – < 75 – –
Amsorb Armstrong, Coleraine,
Northern Ireland
– – 83 0.7 –
AmsorbPlus Armstrong, Coleraine,
Northern Ireland
– – 83.2 0.7
Table 2 Peak CO concentrations in
laboratory experiments.
Reference Inhalation agent
Peak CO
concentration
(parts/106) Temperature
CO2
absorbent
Fang (1995) [5] 3.6% sevoflurane 79 60 C Soda lime
Strauss (1996) [14] Enflurane ⁄ isoflurane 3500 52.1 C Soda lime
Stabernack (2000) [23] Desflurane 36 000 Dried Baralyme
Wissing (2001) [25] 5% sevoflurane 1600 130 C Dra¨gersorb 800
Holak (2003) [13] 2.1% sevoflurane 11 000 > 110 C Dried Baralyme
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breathing tubing. With dried CO2 absorbent and sevo-
flurane, no sevoflurane could be detected for about
20 min, followed by a short-lasting overshoot (about
twice the vapour dial). An irritating smell was also
noticed. In a Dra¨ger circle system, sevoflurane 8% in O2
6 l.min)1 was washed into the canister in which there was
previously dried Dra¨gersorb 800 (containing potassium
hydroxide (KOH)) or Sofnolime (KOH free) CO2
absorbent [16]. With dry soda lime, sevoflurane could
not be measured before 3 min but compound A and
methanol were detectable after only 1 min, with an
absorbent peak temperature of 110 C. Formaldehyde
was detected only with dry soda lime. Significant
interaction with inhalation anaesthetics was not observed
if the water content of the CO2 absorbent was > 5%.
Sevoflurane degradation was aggravated by high KOH
content of the lime. It was suggested that clinical airway
irritation might be caused by formic acid, which is
generated with methanol by the Cannizzaro reaction
(Fig. 2), in which certain aldehydes may undergo in
concentrated alkali: one molecule of the aldehyde is
reduced to the corresponding alcohol and another
molecule is simultaneously oxidised to the salt of a
carboxylic acid.
Animal studies
Baralyme was ‘conditioned’ by passing a 5 l.min)1 O2
flow through the canister for 40 h [17]. Pigs were
anaesthetised with a rebreathing circuit containing the
dehydrated Baralyme and using sevoflurane, aiming at
an end-tidal concentration of 3.0–3.2%. Compound A
peaked at a concentration of 357 parts per million and the
Baralyme temperature at 310 C. However, in one
experiment the temperature rose very rapidly, reaching
401 C after 80 min, the absorbent began to melt,
smoulder and smoke appeared in the circuit. CO
Figure 1 Simplified mechanism of car-
bon monoxide (CO) formation from
desflurane (Baxter); the source of CO is
the –CF2 moiety.
Figure 2 Cannizzaro reaction showing the production of methanol (from Morio et al. [21], with permission).
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concentrations were not analysed. In the study by Frink
et al. [12] Baralyme or soda lime dried for 24 or 48 h was
used while anaesthetising pigs with desflurane in a
conventional circle system. Extremely high COHb
concentrations of > 80% were found with Baralyme
dried for 48 h. For CO2 absorbents dried for 24 h, peak
CO concentrations of 8800–13 600 parts per million
were reached. Peak COHb concentrations of 73% for
Baralyme and 53% for soda lime were recorded with
absorbent temperatures of 50 C. Sevoflurane was not
assessed in this study.
Clinical information
In a large clinical trial of patients having low-flow
anaesthesia, no evidence of accidental CO intoxication
was found when the CO2 absorbent was properly
maintained [18]. Severe CO poisoning during desflurane
anaesthesia has been reported [19]: in a 24-year-old
woman during 5% desflurane anaesthesia in the presence
of dehydrated Baralyme, the SpO2 decreased to 93% and
HbO2 to 63%, and 36% COHb was found. She recovered
completely after immediate replacement of the Baralyme.
Five cases were reported in which sevoflurane reacted
with accidentally dried soda lime [20]. In a 14-year-old
girl, despite a vapour concentration of 8% sevoflurane
on the dial, an effective circuit concentration of less than
1% was found; the insufflation pressure was high at
45 cm H2O and the O2 saturation decreased to 81%,
followed by coughing, tachycardia and cyanotic skin
colouration. Arterial blood gas analysis revealed a COHb
concentration of 4.4% (Table 3). The soda lime turned
dark blue and subsequent analysis showed a water con-
centration of only 1.3%. The girl had to be ventilated for
1 day, and had coughing and mild dyspnoea for some
days, but she had recovered completely by the 9th day. In
a 2-year-old boy, induction with 4% sevoflurane by mask
produced intense coughing and, despite an increase to 7%
sevoflurane, induction was not successful in the next
15 min, with coughing and extreme salivation. It was
noticed that the CO2 absorbent had turned blue and that
the canister was extremely hot, while a pungent smell
escaped. An arterial sample revealed a COHb concentra-
tion of 8.4%, which decreased to 3.4% after 3 h
ventilation. Subsequent analysis of the soda lime showed
that it was completely dry, as it had not been changed for
3 weeks. In another 2-year-old boy, induction with 7%
sevoflurane by mask produced intense coughing and
salivation. The breathing gases had an irritating smell, the
breathing tubes were hot and water vapour was gener-
ated. The CO2 absorber felt overheated and the CO2
absorbent turned blue; subsequent analysis showed a
water content of 0.5%. In two inductions with sevoflu-
rane 2.5% in boys weighing 18 and 22 kg, less than the
expected concentrations were found: in the first, chan-
ging to isoflurane resolved the problem, while in the
second, a blue colouration of the CO2 absorbent was
noticed; the O2 saturation was unchanged. After changing
the CO2 absorber, anaesthesia progressed without prob-
lems. It was found that the CO2 absorbent in the
induction room had not been changed for 3 weeks. All
the above-mentioned cases fortunately recovered, thanks
to early diagnosis and appropriate measures. They clearly
show that in routine clinical practice, sevoflurane reacts
with accidentally desiccated CO2 absorbents by absorp-
tion and ⁄ or destruction of the anaesthetic and with
intense heat generation. In another published case, a
46-year-old woman could not be induced with 5%
sevoflurane, but the temperature of the absorbent canister
increased sharply and the Dra¨gersorb 800 absorbent
turned blue, with condensing water visible in the tubing.
Subsequent analysis showed a water content of < 1% [21].
Studies in the last 5 years with more modern
CO2 absorbents
During the last 5 years, the particular importance of the
chemical composition and brand of the CO2 absorbent
has been recognised. The strong alkali hydroxides, KOH
and sodium hydroxide (NaOH), were held responsible
for the decomposition of inhalation anaesthetics and
elimination of these substances have made the CO2
absorbent safer, as tested in a study published in 1999 [22].
That study, using barrels of 30-ml syringes, demonstrated
Table 3 Published clinical reactions with sevoflurane.
Patient (age or
body weight, sex)
Inspired
sevoflurane Clinical problems Oxygenation Absorbent characteristics
14 year, $ 8% Coughing, tachycardia O2 sat ¼ 81%; COHb ¼ 4.4% Blue; H2O ¼ 1.3%
2 year, # 7% Coughing, salivation COHb ¼ 8.4% Blue, hot; dry
2 year, # 7% Coughing, salivation O2 saturation normal Blue; H2O ¼ 0.5%
18 kg, # 2.5% Concentration not reached
22 kg, # 2.5% Concentration not reached O2 saturation normal Light blue; hot
46 year, $ 5% Concentration not reached Blue, hot; H2O < 1%
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that NaOH and KOH are the primary determinants of
the degradation of desflurane to CO, and that they
modestly augment the production of compound A from
sevoflurane. Elimination of these bases in the desiccated
lime decreased CO production 10-fold and decreased
compound A by 41%. In a further study, it was shown
that absorbents differ enormously in their capacity to
produce compound A and CO [23]. Again, 30-ml barrels
immersed in water at 45 C (at 80 C for lithium
hydroxide (LiOH)) were used. The highest CO produc-
tion with desflurane was found with Baralyme (36 100
parts per million) dried for 24 h; minimal or no CO
occurred with dried Amsorb (containing no NaOH or
KOH) and LiOH. In an in vitro experiment, it was found
that when exposed to desflurane, enflurane or isoflurane,
dehydrated Amsorb produced only minimal CO (1.2, 2.3
and 1.5 parts per million, respectively) [24]. Unfortu-
nately, in these last three studies, the production of CO
with sevoflurane was not assessed. When different
inhalation agents were passed from bottom to top through
a Dra¨ger ISO canister filled with Dra¨gersorb 800
(containing NaOH and KOH) dried for at least 72 h,
intense CO formation was noticed with desflurane,
enflurane and isoflurane [25]. A smaller but significant
production of 1600 parts per million CO was found with
5% sevoflurane, at or after the canister temperature
increased to 130 C. This temperature increase was much
higher than with the other anaesthetics. CO production
ceases when heat reaches its maximum at the outlet of the
canister. The temperature increase seems to precede the
production of CO with sevoflurane. In another report, it
was suggested that CO could be formed as a reaction
product from hexafluoroisopropanol, postulated as an
intermediate of sevoflurane degradation [26]. In pigs it has
been shown that dried Amsorb (NaOH- and KOH-free
absorbent), in contrast to classic soda limes, produced
minimal if any CO with desflurane and isoflurane [27].
Sevoflurane was not examined in this context, but dried
Amsorb caused negligible formation of compound A with
sevoflurane. Consistent with the lack of compound A
formation, dehydrated Amsorb did not increase COHb
concentrations [27]. During an in vitro study with two
new-generation absorbents, Dra¨gerSorb Free and Amsorb
Plus, it was found that with desflurane, no CO was
formed with either dehydrated absorbent [28], but
regrettably sevoflurane was not examined for CO
production.
The Holak in vitro study is the most convincing report of
the possible dangers of CO generation with sevoflurane
and dry CO2 absorbents [13]. The study simulated
respiration by the addition of CO2 to an artificially
ventilated circuit. Baralyme that had been desiccated for at
least 1 week was examined, together with sevoflurane at a
2.1% end-tidal concentration (1 MAC). No significant
degree of anaesthetic breakdown or CO production was
noticed with normally hydrated Baralyme. Desiccated
absorbent produced measurable sevoflurane breakdown;
1 MAC could not be obtained with 2 l.min)1 fresh gas
flow, despite a vaporiser output of 8%. Under other
conditions, CO concentrations of 239–542 parts per
million were recorded. Most clinically relevant, CO
concentrations did not occur until the absorbent tempera-
ture exceeded 80 C. The absorbent in the upper canister
turned blue. In one particular condition, the upper canister
was heated to > 110 C and turned blue within 10 min.
An exponential increase in CO concentration began,
exceeding 11 000 parts per million after 50 min. Some-
what later, an explosion occurred, together with a flash of
light in the breathing circuit. Just before the explosion,
formaldehyde and methanol were detected but were not
quantified. Interestingly, at no time did the infrared gas
monitor detect an erroneous anaesthetic. Holak suggests
that CO production depends on the temperature of the
absorbent and that 80 C may be the temperature
threshold for important CO production [13]. It is likely
that methanol, formaldehyde, CO and sevoflurane all
contributed to the development of a flammable gas
mixture. In a recent in vitro study [29], desiccated Baralyme
was used in an artificially ventilated circuit. With desflu-
rane and isoflurane (1.5 and 3.0 MAC, respectively) the
canister temperature increased to a maximum of 100 C.
However, with sevoflurane (1.5 MAC) the temperature
increased to over 200 C and, in two of five runs, flames
appeared in the anaesthetic circuit.
The general problem of CO generation with
inhalation agents
It is now evident that in particular circumstances CO can
be formed during sevoflurane administration. A dry CO2
absorbent seems to be essential for this occurrence, and
from the published data, it appears that Baralyme is the
most reactive absorbent. Although Baralyme is now an
outmoded CO2 absorbent and is not used in Europe,
other absorbents are also reactive. Formal studies are still
needed on all the newer NaOH- and KOH-free CO2
absorbents. Holak’s report [13] was so important that it
provoked the sending of a ‘Dear doctor’ letter in the USA
by the makers of sevoflurane, pointing to the clinical
importance of the problem and stressing the need to avoid
using dry CO2 absorbent. An unusually delayed rise or
unexpected decline of inspired sevoflurane concentration
compared to the vaporiser setting may be associated with
excessive heating of the CO2 absorbent canister. Lack of
significant colour change should not be taken as an
assurance of adequate hydration of the CO2 absorbent.
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Measures to prevent accidental drying of
the CO2 absorbent in clinical use
Firm guidelines on the use of anaesthetic machines should
prevent accidental drying of the CO2 absorbent contained
in the canister of the breathing circuit [20, 30]. After the
anaesthetic, the gas flows should be turned off completely,
particularly at the end of the day. The CO2 absorbent
should be changed routinely regardless of the state of the
colour indicator and certainly if the machine has not been
used for some time. Flushing of the breathing circuit with
fresh gas before use will not prevent CO exposure [31].
If the gas flow has not been shut off during the night
or weekend, the absorbent should be replaced in both
canisters [32]. If excessive heat from the CO2 absorbent
canister is noted, the absorbent should be replaced and the
patient monitored for CO exposure. There is also a case
for using low-flow anaesthesia techniques to preserve the
water contained in the CO2 absorbent.
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